Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.
